Beckwith-Wiedemann syndrome (BWS) is a rare genetic disorder characterized by genetic and epigenetic changes on the chromosome 11p15.5 region, which includes genes that are important for fetal and postnatal growth. Children with BWS have a higher chance of having hypoglycemia, hyperinsulinemia, and malignancies early in life, although hypoglycemia caused by an insulinoma that develops later in life has not been reported. We describe the diagnosis of insulinoma in a 53-year-old man with BWS in this case report. This is the first case report of insulinoma in an adult with this syndrome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580426 | PMC |
| http://dx.doi.org/10.1210/jcemcr/luad062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Review of Multiple Endocrine Neoplasia Type 1 Based on a Clinical Case].
Rev Med Chil
June 2024
Departamento de endocrinología, Hospital Clínico San Borja Arriarán, Santiago, Chile.
Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disease with an estimated prevalence of 2 per 100,000. This disease is caused by a mutation in the tumor suppressor gene MEN1, which is located on chromosome 11 and codifies the menin protein. It is characterized by a predisposition of parathyroids, enteropancreatic, and anterior pituitary tumors, affecting the quality of life and lifespan of those who have the disease.
View Article and Find Full Text PDFInsulinoma: Unraveling the Mystery of a Stealthy Culprit.
Cureus
November 2024
Endocrinology and Diabetes, Nottingham University Hospitals National Health Service (NHS) Trust, Nottingham, GBR.
Insulinoma, a rare pancreatic neuroendocrine tumor, stealthily lurks within the pancreas, often evading detection until its distinctive symptom, recurrent hypoglycemia, comes to the surface. This case report aims to highlight the significance of a multidisciplinary approach in the management of this uncommon neuroendocrine tumor by discussing the diagnostic, therapeutic, and follow-up difficulties encountered in an older adult presenting with atypical symptoms of insulinoma.
View Article and Find Full Text PDFCalcium sensing receptor expression is downregulated in gastroenteropancreatic neuroendocrine tumours via epigenetic mechanisms.
Int J Cancer
March 2025
OCDEM, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Article Synopsis
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can be either hormone-secreting or non-secreting, have serious health implications, and an average survival of 75-124 months.
- Research shows that key genes involved in the tumor's development, especially epigenetic regulators like MEN1, DAXX, and ATRX, are often mutated, but their effects are not well understood.
- The calcium sensing receptor (CaSR) is significantly reduced in GEP-NETs, potentially due to DNA methylation and chromatin modifications, suggesting it functions as a tumor suppressor by inhibiting cell growth in pancreatic NETs.
Robotic-assisted pancreatic enucleation: Posterior uncinate approach.
Updates Surg
December 2024
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Article Synopsis
- - Functional pancreatic neuroendocrine tumors (pNET) require surgical removal, with enucleation being the top choice for small, well-differentiated tumors under 2 cm.
- - Insulinomas, a type of pNET, are ideal candidates for enucleation, but surgeries involving the uncinate process of the pancreas can be complex.
- - A video demonstrates a successful robotic-assisted enucleation of an insulinoma in a 41-year-old man, resulting in symptom relief and low post-operative complications.
Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.
Clin Nucl Med
January 2025
From the Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Article Synopsis
- A study was conducted to compare a new GLP-1R-targeted PET agent, 68 Ga-HBED-CC-exendin-4, with an older version, 68 Ga-NOTA-exendin-4, for locating insulinoma in patients with hyperinsulinemic hypoglycemia.
- Both agents demonstrated 100% sensitivity, but 68 Ga-HBED-CC-exendin-4 had a lower tumor uptake value compared to 68 Ga-NOTA-exendin-4, although both maintained similar tumor-to-background ratios.
- The new agent also showed a significant reduction in renal accumulation, potentially enhancing the detection of tumors located near the kidney.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!